Antimicrobial Agents and Chemotherapy · 2018 · 60 citations · 38 references
Life SciencesInfectious DiseasesPharmacologyClinical PharmacologyMolecular VirologyVirologyAntiviral AgentsAntiviral Drug ResistanceAntiviral ResistanceAntiviral TherapyNucleos(t)ide Analog TherapyViral HepatitisAdefovir Dipivoxil TherapyChronic Viral HepatitisComparative Clinical TrialsHepatitis B TherapyHepatitis B Virus ResistancePharmacovigilance Of Hepatitis TherapiesPhenotypic Data AnalysisTenofovir Therapy
After 96 weeks, the proportion of patients achieving virus suppression (HBV DNA < 69 IU/ml) was similar across treatment groups, and no substitutions associated with resistance to TAF or TDF were detected. (These studies have been registered at ClinicalTrials.gov under identifiers NCT01940471 and NCT01940341.).
38
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Patrick Marcellin, E. Jenny Heathcote, Ed Gane et al. · New England Journal of Medicine · 2008 · 1.2K citations · Full text
European Journal Of Haematology · 2015 · 791 citations
Long-term safety of lamivudine treatment in patients with chronic hepatitis B
Anna S. Lok, Ching‐Lung Lai, Nancy Leung et al. · Gastroenterology · 2003 · 767 citations · Full text